- Have any questions?
- 862-258-5500
- tdsteele@outlook.com
Regulatory expectations for nonclinical safety programs are complex, continually evolving, and often open to interpretation. Nonclinical Safety Solutions (NCSS) provides expert regulatory strategy and risk assessment services to ensure development plans are scientifically justified, defensible, and aligned with global standards. With deep experience as both a senior industry toxicologist and a former FDA Pharmacology/Toxicology reviewer, Dr. Thomas D. Steele offers rare insight into how regulators evaluate nonclinical data—and how to position that data for productive, efficient regulatory interactions.
A strong regulatory strategy prevents delays, minimizes unexpected questions, and ensures the nonclinical package supports timely clinical progression. NCSS evaluates existing data, identifies risks or gaps, and develops a clear, cohesive plan that integrates toxicology, pharmacology, PK/ADME, and safety pharmacology into a unified safety narrative. Whether preparing an IND, interpreting complex findings, or navigating evolving regulatory guidance, NCSS provides strategic clarity at every stage of development.
Effective risk assessment is equally essential. NCSS helps teams understand safety signals in the appropriate biological and regulatory context, determine human relevance, construct meaningful safety margins, and articulate scientifically sound rationales. This proactive approach strengthens regulatory submissions and supports confident, informed internal decision-making throughout development.
Regulatory strategy is not a checklist—it requires scientific judgment, anticipation of reviewer concerns, and a defensible rationale for every decision. Misinterpreting guidance or overlooking a critical data gap can lead to costly delays, unnecessary studies, or FDA/EMA requests that disrupt development timelines. NCSS helps teams identify these risks early and address them proactively.
With decades of experience preparing and reviewing regulatory submissions, Dr. Steele delivers strategies that are both practical and scientifically rigorous. His combined perspectives—from both the sponsor side and inside the FDA—provide a clear understanding of how regulators evaluate risk and what strengthens a nonclinical safety argument.
If you would like expert regulatory guidance or need support evaluating safety risk and data gaps, please request a consultation so NCSS can assess your program and provide clear, science-based recommendations.
A regulatory risk assessment evaluates toxicology, pharmacology, PK/ADME, and study design to identify safety risks, data gaps, and potential regulatory concerns prior to submission.
A well-constructed strategy helps ensure studies are appropriately designed, sequenced, and justified—minimizing the likelihood of FDA questions, clinical holds, or requests for additional data.
Yes. NCSS supports preparation of briefing documents, safety arguments, data summaries, and strategic positioning to enable productive and efficient regulatory interactions.
As early as possible—ideally during discovery or lead optimization—so timelines, study expectations, and development decisions align with regulatory requirements.
NCSS evaluates findings in the appropriate regulatory context, determines potential clinical relevance, and develops mechanistic explanations or follow-up strategies to mitigate risk.
Yes. NCSS provides guidance aligned with FDA, EMA, and global ICH frameworks to support consistent and compliant worldwide development strategies.